Caribou Biosciences, Inc. (CRBU)

USD 0.8

(-8.48%)

Market Cap (In USD)

74.42 Million

Revenue (In USD)

34.47 Million

Net Income (In USD)

-102.07 Million

Avg. Volume

1.15 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.5-8.33
PE
-0.48
EPS
-1.65
Beta Value
2.263
ISIN
US1420381089
CUSIP
142038108
CIK
1619856
Shares
93004600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rachel E. Haurwitz Ph.D.
Employee Count
-
Website
https://cariboubio.com
Ipo Date
2021-07-23
Details
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.